A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma

Trial Profile

A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-022
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Updated results from phase-I part of the study (n=15; data cut off: 1 Mar, 2017) presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
    • 22 Mar 2017 Planned End Date changed from 1 Sep 2018 to 10 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top